BIOA Pengajuan SEC - BioAge Labs, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1534287

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BioAge Labs, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

February 14, 2019	SC 13D/A	BIOA / BioAmber Inc. / SOFINNOVA CAPITAL VI FCPR - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
February 8, 2019	SC 13G/A	BIOA / BioAmber Inc. / INTRACOASTAL CAPITAL, LLC - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* BioAmber Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 09072Q106 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu
October 26, 2018	8-K	Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2018 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Commission File Num
October 26, 2018	EX-99.1	BioAmber Provides Update on Liquidation Process EX-99.1 Exhibit 99.1 BioAmber Provides Update on Liquidation Process Montreal, Canada, October 25, 2018. PricewaterhouseCoopers Inc., LIT, in its capacity as the court-appointed Monitor (in such capacity, the “Monitor”) of BioAmber Inc. (OTCPK: BIOAQ), BioAmber Canada Inc., and BioAmber Sarnia Inc. (collectively, the “Company”) in their proceedings under the Companies Creditors’ Arrangement Act, R
August 31, 2018	EX-99.1	BioAmber Provides Update on Liquidation Process & Announces Resignations of Board Members and Officers EX-99.1 Exhibit 99.1 BioAmber Provides Update on Liquidation Process & Announces Resignations of Board Members and Officers Montreal, Canada, August 31, 2018. BioAmber Inc. (the “Company”) (OTCPK: BIOAQ) announces that following a Court order issued on August 28th, 2018, the stay period ordered by the Court in connection with its restructuring process under the terms of the Companies’ Creditors Ar
August 31, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2018 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Commission File Numb
August 14, 2018	EX-99.1	BioAmber Provides Update on Liquidation Process EX-99.1 Exhibit 99.1 BioAmber Provides Update on Liquidation Process Montreal, Canada, August 9, 2018. BioAmber Inc. (OTCPK: BIOAQ) announces that following a court order issued on July 31, 2018, the company, along with its monitor, PricewaterhouseCoopers (PWC), has initiated a liquidation process pursuant to which offers will be solicited from liquidators and/or strategic buyers to proceed with t
August 14, 2018	8-K	Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2018 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Commission File Numbe
August 1, 2018	8-K	Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2018 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Commission File Number
August 1, 2018	EX-99.1	BioAmber Provides Update on Sales Process EX-99.1 Exhibit 99.1 BioAmber Provides Update on Sales Process Montreal, Canada, July 30, 2018. BioAmber Inc.
June 20, 2018	EX-99.1	BioAmber Receives Favourable Court Ruling and Approval for DIP Financing EX-99.1 Exhibit 99.1 BioAmber Receives Favourable Court Ruling and Approval for DIP Financing Montreal, Canada, June 18, 2018. BioAmber Inc. (OTCPK: BIOA) (“BioAmber”) announced today that it has received formal Quebec court approval for debtor-in-possession (DIP) financing. This funding will enable the execution of the Sales and Investor Solicitation Process (SISP) that commenced on June 1, 2018,
June 20, 2018	8-K	Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2018 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Commission File Number
June 7, 2018	EX-99.1	IDENTITY AND THE ITEM 3 CLASSIFICATION OF THE RELEVANT SUBSIDIARIES EX-99.1 Exhibit (99.1) IDENTITY AND THE ITEM 3 CLASSIFICATION OF THE RELEVANT SUBSIDIARIES The securities being reported on by NN Group N.V. (the “Reporting Person”), as a parent holding company, were owned (or may be deemed to have been beneficially owned) by NN Investment Partners B.V. and NN Investment Partners Luxembourg S.A., each of which is a subsidiary of the Reporting Person and a non-U.S
June 7, 2018	SC 13G/A	BIOA / BioAmber Inc. / Nn Group N.v. - SCHEDULE 13G AMENDMENT NO. 2 Passive Investment SC 13G/A 1 d599900dsc13ga.htm SCHEDULE 13G AMENDMENT NO. 2 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 2) BioAmber Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securit
May 9, 2018	NT 10-Q	BIOA / BioAmber Inc. NT 10-Q NT 10-Q 1 d583057dnt10q.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number 001-35905 NOTIFICATION OF LATE FILING CUSIP Number 09072Q106 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2018 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Tra
May 8, 2018	EX-99.1	BioAmber Announces Filing for Stay of Proceedings on Creditors EX-99.1 Exhibit 99.1 BioAmber Announces Filing for Stay of Proceedings on Creditors Montreal, Canada, May 4, 2018. BioAmber Inc. (OTCPK: BIOA) (“Bioamber” or the “company”) announces today that it filed a voluntary petition for relief under chapter 11 of the United States Bankruptcy Code and that its two Canadian subsidiaries, BioAmber Sarnia Inc. and BioAmber Canada Inc., filed a Notice of Intent
May 8, 2018	8-K	Financial Statements and Exhibits, Bankruptcy or Receivership 8-K 1 d582086d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2018 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Com
April 30, 2018	10-K/A	Annual Report - 10-K/A 10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 16, 2018	DEFA14A	BIOA / BioAmber Inc. DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.
March 30, 2018	DEF 14A	BIOA / BioAmber Inc. DEF 14A DEF 14A 1 d543405ddef14a.htm DEF 14A Table of Contents SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission O
March 30, 2018	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35905 BioAmber Inc.
March 30, 2018	EX-10.65	Non-Assertion Agreement, dated as of December 21, 2016, by and between BioAmber Inc. and Mitsubishi Chemical Corporation Exhibit 10.65 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED NON-ASSERTION AGREEMENT This Agreement made and entered into this 21st day of December, 2016 (hereinafter re
March 20, 2018	PRE 14A	BIOA / BioAmber Inc. PRE 14A PRE 14A Table of Contents SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-12 BIOAMBER INC.
March 15, 2018	EX-99.1	March 15, 2018 EX-99.1 Exhibit 99.1 March 15, 2018 BioAmber Inc. 1250 Rene Levesque West, Suite 4310 Montreal, Quebec, Canada H3B 4W8 Pursuant to Rule 12b-25 of the General Rules and Regulations under the Securities Exchange Act of 1934, we inform you that we have been furnished a copy of Form 12b-25 to be filed by BioAmber Inc. on or about March 15, 2018, which contains notification of BioAmber Inc.’s inability
March 15, 2018	NT 10-K	BIOA / BioAmber Inc. NT 10-K NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number 001-35905 NOTIFICATION OF LATE FILING CUSIP Number 09072Q106 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2017 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11
March 9, 2018	EX-99.1	IDENTITY AND THE ITEM 3 CLASSIFICATION OF THE RELEVANT SUBSIDIARIES EX-99.1 Exhibit (99.1) IDENTITY AND THE ITEM 3 CLASSIFICATION OF THE RELEVANT SUBSIDIARIES The securities being reported on by NN Group N.V. (the “Reporting Person”), as a parent holding company, are owned (or may be deemed to be beneficially owned) by NN Investment Partners B.V. and NN Investment Partners Luxembourg S.A., each of which is a subsidiary of the Reporting Person and a non-U.S. instit
March 9, 2018	SC 13G/A	BIOA / BioAmber Inc. / Nn Group N.v. - SCHEDULE 13G AMENDMENT NO. 1 Passive Investment SC 13G/A 1 d545159dsc13ga.htm SCHEDULE 13G AMENDMENT NO. 1 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 1) BioAmber Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securit
February 27, 2018	EX-99.25	EX-99.25 NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange ('NYSE' or the 'Exchange') hereby notifies the Securities and Exchange Commission (the 'Commission') of its intention to remove the entire class of the common stock (the 'Common Stock') of BioAmber, Inc.
February 20, 2018	SC 13G	BIOA / BioAmber Inc. / INTRACOASTAL CAPITAL, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BioAmber Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 09072Q106 (CUSIP Number) February 9, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan
February 16, 2018	EX-99.1	BioAmber Inc. Receives Notice of Delisting by TSX EX-99.1 Exhibit 99.1 BioAmber Inc. Receives Notice of Delisting by TSX Montreal, Canada, February 16, 2018. BioAmber Inc. (OTCPK: BIOA) announced today that the Toronto Stock Exchange (TSX) has notified the Company that it has determined to suspend trading in the Company?s shares of common stock, effective February 16, 2018, and to delist the Company?s securities effective at the close of market o
February 16, 2018	8-K	Regulation FD Disclosure, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits 8-K 1 d541046d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2018 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation
February 15, 2018	EX-99.1	BioAmber Inc. Receives Notice of Delisting Review by TSX EX-99.1 Exhibit 99.1 BioAmber Inc. Receives Notice of Delisting Review by TSX Montreal, Canada, February 13, 2018. BioAmber Inc. (TSX: BIOA) announced today that the Toronto Stock Exchange (TSX) has notified the Company that it is reviewing, on an expedited basis, the Companys eligibility for continued listing. This review results from the Company not being in a position to obtain the approval of
February 15, 2018	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 d518489d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2018 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation
February 13, 2018	424B5	BioAmber Inc. 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-215408 Prospectus Supplement to Prospectus dated January 12, 2017 BioAmber Inc. 15,969,166 Series A Units consisting of one share of Common Stock, one Series A Common Warrant to purchase one share of Common Stock and one Series B Common Warrant to purchase one share of Common Stock and one Series C Common Warrant to purc
February 12, 2018	EX-4.3	Form of Series C Warrant to Purchase Common Stock of BioAmber Inc. EX-4.3 Exhibit 4.3 SERIES C COMMON STOCK PURCHASE WARRANT BIOAMBER INC. Holder Subscription Amount: $ Initial Exercise Date: February , 2018 THIS SERIES C COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or af
February 12, 2018	EX-99.1	BioAmber Inc. Announces Registered Direct Offering; Termination of Underwriting Agreement for Previously-Announced Public Offering EX-99.1 7 d520750dex991.htm EX-99.1 Exhibit 99. 1 BioAmber Inc. Announces Registered Direct Offering; Termination of Underwriting Agreement for Previously-Announced Public Offering MONTREAL, Feb. 9, 2018 /PRNewswire/-BioAmber Inc. (NYSE: BIOA) (TSX: BIOA) (“BioAmber” or the “Company”), announced today that it has entered into definitive agreements with certain institutional investors to purchase a
February 12, 2018	EX-4.4	Form of Pre-Funded Warrant to Purchase Common Stock of BioAmber Inc. EX-4.4 Exhibit 4.4 PREFUNDED COMMON STOCK PURCHASE WARRANT BIOAMBER INC. Warrant Shares: Initial Exercise Date: February , 2018 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after February
February 12, 2018	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits 8-K 1 d520750d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2018 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation)
February 12, 2018	EX-1.1	Securities Purchase Agreement, dated as of February 9, 2018, between the Company and the purchasers party thereto. EX-1.1 Exhibit 1.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of February 9, 2018 between BioAmber Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions se
February 12, 2018	EX-4.1	Form of Series A Warrant to Purchase Common Stock of BioAmber Inc. EX-4.1 3 d520750dex41.htm EX-4.1 Exhibit 4.1 SERIES [A/B] COMMON STOCK PURCHASE WARRANT BIOAMBER INC. Warrant Shares: Initial Exercise Date: February , 2018 THIS SERIES [A/B] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth,
February 9, 2018	424B5	SUBJECT TO COMPLETION, DATED FEBRUARY 9, 2018 Prospectus Supplement to Prospectus dated January 12, 2017 BioAmber Inc. 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-215408 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is no
February 8, 2018	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 d522224d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2018 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation)
February 8, 2018	EX-4.3	Form of Pre-Funded Warrant to Purchase Common Stock of BioAmber Inc. EX-4.3 4 d522224dex43.htm EX-4.3 Exhibit 4.3 PREFUNDED COMMON STOCK PURCHASE WARRANT BIOAMBER INC. Warrant Shares: Initial Exercise Date: February , 2018 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any
February 8, 2018	EX-1.1	Underwriting Agreement dated as of February 6, 2018, by and between BioAmber Inc. and H.C. Wainwright & Co., LLC. EX-1.1 Exhibit 1.1 Underwriting Agreement February 6, 2018 H.C. Wainwright & Co., LLC As the Representative of the Several underwriters, if any, signatory hereto and named in Schedule I hereto 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: BioAmber Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell to the Und
February 8, 2018	EX-99.1	BIOAMBER INC. ANNOUNCES PRICING OF US$10 MILLION UNDERWRITTEN PUBLIC OFFERING EX-99.1 Exhibit 99.1 BIOAMBER INC. ANNOUNCES PRICING OF US$10 MILLION UNDERWRITTEN PUBLIC OFFERING Montreal, Canada, February 6, 2018. BioAmber Inc. (NYSE: BIOA; TSX: BIOA) (BioAmber or the Company) announced today that it has priced an underwritten public offering of an aggregate of 40 million Series A units (or equivalent Series B Units), with each Series A unit consisting of one share of co
February 8, 2018	EX-4.1	Form of Series B Warrant to Purchase Common Stock of BioAmber Inc. (included in Exhibit 4.1). EX-4.1 Exhibit 4.1 SERIES [A/B] COMMON STOCK PURCHASE WARRANT BIOAMBER INC. Warrant Shares: Initial Exercise Date: February , 2018 THIS SERIES [A/B] COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after Fe
February 8, 2018	424B5	BioAmber Inc. 32,300,000 Series A Units consisting of one share of Common Stock, one Series A Common Warrant to purchase one share of Common Stock and one Series B Common Warrant to purchase one share of Common Stock 7,700,000 Series B Units consisti 424B5 1 d372617d424b5.htm 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-215408 Prospectus Supplement to Prospectus dated January 12, 2017 BioAmber Inc. 32,300,000 Series A Units consisting of one share of Common Stock, one Series A Common Warrant to purchase one share of Common Stock and one Series B Common Warrant to purchase one share of Common Stock 7,700,000 Ser
February 6, 2018	8-K/A	Regulation FD Disclosure, Financial Statements and Exhibits 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2018 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Commission File
February 6, 2018	424B5	SUBJECT TO COMPLETION, DATED FEBRUARY 5, 2018 424B5 1 d372617d424b5.htm 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-215408 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction whe
February 5, 2018	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 d535886d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2018 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation)
February 5, 2018	EX-10.1	Waiver to Loan Agreement, dated February 5, 2018, among BioAmber Sarnia Inc., Comerica Bank and the other parties thereto EX-10.1 Exhibit 10.1 WAIVER THIS WAIVER (this ?Waiver?) is made as of February , 2018 AMONG: BIOAMBER SARNIA INC. as Borrower -and- THE LENDERS PARTY HERETO -and- COMERICA BANK as Agent BACKGROUND WHEREAS pursuant to a loan agreement dated as of June 20, 2014, as amended by a waiver and first amending agreement dated May 12, 2015, a waiver, consent and second amending agreement dated August 9, 201
February 5, 2018	EX-99.1	BIOAMBER INC. ANNOUNCES UNDERWRITTEN OFFERING EX-99.1 Exhibit 99.1 BIOAMBER INC. ANNOUNCES UNDERWRITTEN OFFERING Montreal, Canada, February 5, 2018. BioAmber Inc. (NYSE: BIOA; TSX: BIOA) (?BioAmber? or the ?Company?) announced today that it has commenced an underwritten public offering of its Series A units, with each Series A unit consisting of one share of common stock, one Series A warrant to purchase one share of common stock and one Seri
February 5, 2018	424B5	SUBJECT TO COMPLETION, DATED FEBRUARY 5, 2018 424B5 1 d372617d424b5.htm 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-215408 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction whe
January 26, 2018	EX-10.1	Waiver and Third Amending Agreement to Loan Agreement, dated as of September 26, 2017, among BioAmber Sarnia Inc., Comerica Bank and the other parties thereto EX-10.1 2 d460213dex101.htm EX-10.1 Exhibit 10.1 WAIVER AND THIRD AMENDING AGREEMENT TO LOAN AGREEMENT THIS WAIVER AND THIRD AMENDING AGREEMENT (this “Agreement”) is made as of September 26, 2017 AMONG: BIOAMBER SARNIA INC. as Borrower - and - THE LENDERS PARTY HERETO - and - COMERICA BANK as Agent BACKGROUND WHEREAS pursuant to a loan agreement dated as of June 20, 2014 (as amended by a waiver an
January 26, 2018	EX-10.2	Waiver and Fourth Amending Agreement to Loan Agreement, dated as of January 25, 2018, among BioAmber Sarnia Inc., Comerica Bank and the other parties thereto EX-10.2 Exhibit 10.2 WAIVER AND FOURTH AMENDING AGREEMENT TO LOAN AGREEMENT THIS WAIVER AND FOURTH AMENDING AGREEMENT (this ?Agreement?) is made as of January 25, 2018 AMONG: BIOAMBER SARNIA INC. as Borrower -and- THE LENDERS PARTY HERETO -and- COMERICA BANK as Agent BACKGROUND WHEREAS pursuant to a loan agreement dated as of June 20, 2014 (as amended by a waiver and first amending agreement dated
January 26, 2018	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2017 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Commission File N
January 17, 2018	CORRESP	BIOA / BioAmber Inc. CORRESP CORRESP 1 filename1.htm Confidential Treatment Requested by BioAmber Inc. BIOA-0001 BioAmber Inc. NYSE: BIOA 1250 Rene Levesque Boulevard West, Suite 4310 Montreal (Quebec) Canada H3B 4W8 w: 514.844.8000 f: 514.844.1414 FOIA Confidential Treatment Request The entity requesting confidential treatment is BioAmber Inc. 1250 Rene Levesque Boulevard West, Suite 4310 Montreal (Quebec) Canada H3B 4W8 Att
November 8, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 bioa-8k20171107.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2017 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporat
November 8, 2017	EX-99.1	BioAmber Announces Third Quarter 2017 Financial Results bioa-ex99115.htm Exhibit 99.1 BioAmber Announces Third Quarter 2017 Financial Results Montreal, Canada, November 7th, 2017. BioAmber Inc. (NYSE: BIOA, TSX: BIOA) ? a leader in renewable materials today announced operational and financial results for the three months ended September 30, 2017. Highlights: ? Sales of bio-succinic acid were $3.3m, compared to $3.7m in Q3 2016. Nine months sales ended
November 8, 2017	10-Q	BIOA / BioAmber Inc. 10-Q- 09302017 (Quarterly Report) è UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35905 BIOAMBER INC.
November 8, 2017	EX-10.1	Employment Agreement by and among BioAmber Inc. and Richard P. Eno dated September 11, 2017 Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT ENTERED INTO as of September 13, 2017. BETWEEN: BIOAMBER INC., a corporation duly incorporated in Delaware, having a corporate office located at 1250 Rene-Levesque West, Suite 4310, Montreal, Quebec, H3B 4W8, represented for the purposes hereof by Mr. Ray Land, its Chairman of the Board, duly authorized as he so declares; (hereinafter referred
October 27, 2017	CORRESP	BIOA / BioAmber Inc. CORRESP Via E-mail United States Securities and Exchange Commission 100 F Street, NE Washington, D.
October 24, 2017	EX-99.1	BioAmber President and COO Steps Down bioa-ex9917.htm BioAmber President and COO Steps Down Montreal, Canada, October 24, 2017. BioAmber Inc. (NYSE: BIOA, TSX: BIOA) - The Board of Directors of BioAmber Inc. (?BioAmber?) announced today that it has accepted the resignation of Mr. Fabrice Orecchioni as President and Chief Operating Officer. Mr. Orecchioni will be assuming an advisory role with BioAmber, supporting a series of strategic
October 24, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 bioa-8k20171024.htm 8-K - COO DEPARTURE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2017 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdict
October 24, 2017	EX-10.1	Separation and Consulting Agreement by and between the Company and Fabrice Orecchioni, dated as of October 24, 2017. bioa-ex1016.htm Separation and Consulting Agreement THIS AGREEMENT made as of the 24th day of October, 2017, is entered into between: MR. FABRICE ORECCHIONI, residing and domiciled at 82 Route d?Artix, 64170 Cescau, France (hereinafter referred to as ?Mr. Orecchioni?) and BIOAMBER CANADA INC., a corporation duly incorporated under the Canada Business Corporations Act, having its corporate office l
October 10, 2017	EX-3	POWER OF ATTORNEY Power of Attorney EXHIBIT 3 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, THAT: The undersigned, Waddell & Reed Financial, Inc.
October 10, 2017	EX-1	JOINT FILING AGREEMENT Joint Filing Agreement EXHIBIT 1 JOINT FILING AGREEMENT Waddell & Reed Financial, Inc.
October 10, 2017	EX-2	EXHIBIT 2 Identification and Classification of the Subsidiary Which Acquired the Security EXHIBIT 2 Waddell & Reed Investment Management Company - Tax ID No. 48-1106973 Investment Advisor registered under Section 203 of the Investment Advisors Act of 1940 Ivy Investment Management Company - Tax ID No. 03-0481447 Investment Advisor registered under Section 203 of the Investment Advisors Act of 1940
October 10, 2017	SC 13G/A	BIOA / BioAmber Inc. / WADDELL & REED FINANCIAL INC - BIOAMBER INC. Passive Investment BioAmber Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No. 7* BioAmber Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09072Q106 (CUSIP Number) September 30, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t
September 14, 2017	8-K	BioAmber 8-K (Current Report/Significant Event) bioa-8k20170911.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 11, 2017 BIOAMBER INC. (Exact name of registrant as specified in its charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation
September 14, 2017	EX-99.1	BioAmber Announces New Chief Executive Officer bioa-ex9916.htm Exhibit 99.1 BioAmber Announces New Chief Executive Officer Montreal, Canada, September 14, 2017. BioAmber Inc. (NYSE: BIOA, TSX: BIOA) The Board of Directors of BioAmber Inc. is pleased to announce the appointment of Richard P. Eno as its new Chief Executive Officer, and new member of the Board, effective September 18th, 2017. The selection of Mr. Eno caps a search process facilit
September 13, 2017	8-K	Regulation FD Disclosure, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits 8-K 1 bioa-8k20170908.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2017 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorpora
September 13, 2017	EX-99.1	BioAmber Inc. Receives Notice of Non-Compliance from the NYSE bioa-ex9916.htm Exhibit 99.1 BioAmber Inc. Receives Notice of Non-Compliance from the NYSE Montreal, Canada, September 13, 2017. BioAmber Inc. (NYSE: BIOA, TSX: BIOA) announced today that the New York Stock Exchange (NYSE) has notified the Company that it is no longer in compliance with NYSE listing standards because the price of its common stock has fallen below the NYSE?s share price rule. The N
September 8, 2017	EX-3	POWER OF ATTORNEY Power of Attorney EXHIBIT 3 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, THAT: The undersigned, Waddell & Reed Financial, Inc.
September 8, 2017	EX-2	EXHIBIT 2 Identification and Classification of the Subsidiary Which Acquired the Security EXHIBIT 2 Waddell & Reed Investment Management Company - Tax ID No. 48-1106973 Investment Advisor registered under Section 203 of the Investment Advisors Act of 1940 Ivy Investment Management Company - Tax ID No. 03-0481447 Investment Advisor registered under Section 203 of the Investment Advisors Act of 1940
September 8, 2017	EX-1	JOINT FILING AGREEMENT Joint Filing Agreement EXHIBIT 1 JOINT FILING AGREEMENT Waddell & Reed Financial, Inc.
September 8, 2017	EX-99.1	IDENTITY AND THE ITEM 3 CLASSIFICATION OF THE RELEVANT SUBSIDIARIES EX-99.1 EXHIBIT (99.1) IDENTITY AND THE ITEM 3 CLASSIFICATION OF THE RELEVANT SUBSIDIARIES The securities being reported on by NN Group N.V. (the “Reporting Person”), as a parent holding company, are owned (or may be deemed to be beneficially owned) by NN Investment Partners B.V., NN Investment Partners Luxembourg S.A. and NN Investment Partners TowarzystwoFunduszy Inwestycyjnych S.A., each of whi
September 8, 2017	SC 13G/A	BIOA / BioAmber Inc. / WADDELL & REED FINANCIAL INC - BIOAMBER INC. Passive Investment BioAmber Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No. 6* BioAmber Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09072Q106 (CUSIP Number) August 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
September 8, 2017	SC 13G	BIOA / BioAmber Inc. / Nn Group N.v. - SCHEDULE 13G Passive Investment Schedule 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 BioAmber Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 09072Q106 (CUSIP Number) August 31, 2017 (Date of Event Whi
August 11, 2017	EX-4.2	COMMON STOCK PURCHASE WARRANT bioamber inc. bioa-ex4261.htm Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN E
August 11, 2017	EX-99.3	BIOAMBER INC. ANNOUNCES US$11 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK AND WARRANTS bioa-ex99326.htm Exhibit 99.3 BIOAMBER INC. ANNOUNCES US$11 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK AND WARRANTS Montreal, Canada, August 8, 2017. BioAmber Inc. (NYSE: BIOA; TSX: BIOA) (?BioAmber? or the ?Company?) announced today that it has priced an underwritten public offering of an aggregate of 14,666,667 shares of common stock of the Company, to be sold together in fixed combination wi
August 11, 2017	EX-99.2	BIOAMBER INC. ANNOUNCES UNDERWRITTEN OFFERING OF COMMON STOCK AND WARRANTS bioa-ex99225.htm Exhibit 99.2 BIOAMBER INC. ANNOUNCES UNDERWRITTEN OFFERING OF COMMON STOCK AND WARRANTS Montreal, Canada, August 7, 2017. BioAmber Inc. (NYSE: BIOA; TSX: BIOA) (?BioAmber? or the ?Company?) announced today that it has commenced an underwritten public offering of its common stock, with each share of common stock to be sold together in a fixed combination with a warrant to purchase
August 11, 2017	EX-1.1	Underwriting Agreement bioa-ex1130.htm Exhibit 1.1 Underwriting Agreement August 8, 2017 Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC As the Representative of the Several underwriters, if any, signatory hereto and named in Schedule I hereto 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: BioAmber Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated h
August 11, 2017	EX-99.1	SUBSCRIPTION AGREEMENT bioa-ex99127.htm Exhibit 99.1 SUBSCRIPTION AGREEMENT BioAmber Inc. 1250 Rene Levesque West, Suite 4310 Montreal, Quebec Canada H3B 4W8 Ladies and Gentlemen: Subject to the terms and conditions set forth herein, the undersigned proposes to purchase from BioAmber Inc., a Delaware corporation (the ?Company?), (i) shares of the Company?s common stock, par value $0.01 per share (the ?Shares?) and (ii)
August 11, 2017	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 bioa-8k20170808.htm 8-K-CMPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2017 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorp
August 11, 2017	EX-4.1	COMMON STOCK PURCHASE WARRANT bioamber inc. EX-4.1 3 bioa-ex4129.htm EX-4.1 Exhibit 4.1 COMMON STOCK PURCHASE WARRANT bioamber inc. Warrant Shares: Initial Exercise Date: THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after (the “Initial Exerc
August 9, 2017	424B5	BioAmber Inc. 14,666,667 shares of common stock Warrants to purchase 14,666,667 shares of common stock bioa-424b5.htm Filed pursuant to Rule 424(b)(5) Registration No. 333-215408 Prospectus Supplement to Prospectus dated January 12, 2017 BioAmber Inc. 14,666,667 shares of common stock Warrants to purchase 14,666,667 shares of common stock We are offering 14,666,667 shares of our common stock, par value $0.01 per share, and common stock purchase warrants, or warrants, to purchase up to14,666,667 sha
August 7, 2017	424B5	BioAmber Inc. shares of common stock Warrants to purchase shares of common stock 424B5 1 bioa-424b5.htm BIOA2017-08-07424B5 Filed pursuant to Rule 424(b)(5) Registration No. 333-215408 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the
August 4, 2017	10-Q	BIOA / BioAmber Inc. 10-Q- Q2 2017 (Quarterly Report) 10-Q 1 bioa-10q20170630.htm 10-Q- Q2 2017 è UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission
August 3, 2017	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition, Completion of Acquisition or Disposition of Assets, Other Events 8-K 1 bioa-8k20170801.htm 8-K- Q2 2017- RESULTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2017 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdicti
August 3, 2017	EX-10.3	Security Agreement, dated August 1, 2017, by and among BioAmber Inc., BioAmber Sarnia Inc. and Mitsui & Co., Ltd. bioa-ex10310.htm EXECUTION VERSION Exhibit 10.3 SECURITY AGREEMENT THIS SECURITY AGREEMENT (this ?Agreement?), dated as of August 1st, 2017, is made among Mitsui & Co., Ltd., a corporation organized under the laws of Japan (the ?Secured Party?), BioAmber Inc., a corporation organized under the laws of Delaware (the ?U.S. Grantor?), and BioAmber Sarnia Inc., a corporation organized under the laws o
August 3, 2017	EX-10.1	Share Purchase Agreement, dated August 1, 2017, by and among BioAmber Inc., BioAmber Sarnia Inc. and Mitsui & Co., Ltd. bioa-ex1019.htm EXECUTION VERSION Exhibit 10.1 SHARE PURCHASE AGREEMENT THIS SHARE PURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of the 1st day of August, 2017, by and among BioAmber Inc., a corporation organized under the laws of Delaware (?Buyer?), Mitsui & Co., Ltd., a corporation organized under the laws of Japan (?Seller?), and BioAmber Sarnia Inc., a corporation organized
August 3, 2017	EX-10.2	Share Purchase Agreement, dated August 1, 2017, by and among BioAmber Inc., BioAmber Sarnia Inc. and Mitsui & Co., Ltd. bioa-ex1027.htm EXECUTION VERSION Exhibit 10.2 INDEMNITY AGREEMENT This INDEMNITY AGREEMENT (this ?Agreement?) is made and entered into effective as of August 1st, 2017, by and between, on the one hand, BIOAMBER INC., a corporation organized under the laws of Delaware (?BioAmber?), and BioAmber Sarnia Inc., a corporation organized under the laws of Canada (?BioAmber Sarnia?, and together with BioA
August 3, 2017	EX-99.1	BIOAMBER ANNOUNCES RECORD REVENUES FOR THE SECOND QUARTER 2017 AND PURCHASE OF MITSUI EQUITY STAKE IN SARNIA JOINT VENTURE EX-99.1 5 bioa-ex9918.htm EX-99.1 Exhibit 99.1 BIOAMBER ANNOUNCES RECORD REVENUES FOR THE SECOND QUARTER 2017 AND PURCHASE OF MITSUI EQUITY STAKE IN SARNIA JOINT VENTURE Montreal, Canada, August 3, 2017. BioAmber Inc. (NYSE: BIOA; TSX: BIOA) today announced operational and financial results for the three months ended June 30, 2017 and the purchase and consolidation of the Mitsui & Co Ltd.’s stake
May 15, 2017	EX-99.1	BioAmber Announces Changes to its Board of Directors, the Appointment of a Chief Financial Officer and the Results of its Annual Stockholders Meeting bioa-ex9916.htm BioAmber Announces Changes to its Board of Directors, the Appointment of a Chief Financial Officer and the Results of its Annual Stockholders Meeting MONTREAL, Canada, May 15, 2017 - BioAmber Inc. (NYSE: BIOA) (TSX: BIOA), a leader in renewable materials, today announced that Robert Frost is joining its board of directors, effective today. Mr. Frost will fill one of the board seats
May 15, 2017	EX-10.1	Employment Agreement by and among BioAmber Canada Inc. and Mario Settino dated May 15, 2017 bioa-ex10120.htm EMPLOYMENT AGREEMENT ENTERED INTO as of May 15, 2017. BETWEEN: BIOAMBER CANADA INC., a corporation duly incorporated in Canada, having a business place located at 1250 Rene-Levesque West, Suite 4310, Montreal, Quebec, H3B 4W8, represented for the purposes hereof by Mr. Fabrice Orecchioni, its President, duly authorized as he so declares; (hereinafter referred to as the "Corporatio
May 15, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders 8-K 1 bioa-8k20170515.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 11, 2017 BIOAMBER INC. (Exact name of registrant as specified in its charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorpora
May 10, 2017	10-Q	BioAmber FORM 10-Q (Quarterly Report) 10-Q 1 bioa-10q20170331.htm FORM 10-Q è UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission fil
May 10, 2017	EX-10.1	Amending Agreement #5 thereto dated March 16, 2017 of the Prosperity Initiative Regional Diversification Contribution Agreement effective as of September 16, 2011 between Bluewater Biochemicals, a predecessor entity of BioAmber Sarnia, and Her Majesty the Queen in Right of Canada EX-10.1 2 bioa-ex101192.htm EX-10.1 BIOAMBER SARNIA INC. PROJECT #: 509040 Exhibit 10.1 PROSPERITY INITIATIVE AMENDING AGREEMENT #5 This Amending Agreement made on March 16, 2017 Between: HER MAJESTY THE QUEEN IN RIGHT OF CANADA, (“Her Majesty”) hereby represented by the Minister responsible for the Federal Economic Development Agency for Southern Ontario (“Minister”) And: BIOAMBER SARNIA INC. (“R
May 9, 2017	EX-99.1	BioAmber Reports First Quarter 2017 Financial Results bioa-ex99120.htm Exhibit 99.1 BioAmber Reports First Quarter 2017 Financial Results Montreal, Canada, May 9th, 2017. BioAmber Inc. (NYSE: BIOA, TSX: BIOA), a leader in renewable materials today announced operational and financial results for the three months ended March 31, 2017. Highlights: ? Sales of bio-succinic acid were $2.1 million, a 46% increase over the same period last year. ? There were
May 9, 2017	8-K	BioAmber 8-K Q12017 RESULTS (Current Report/Significant Event) bioa-8k20170509.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2017 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Commissio
May 5, 2017	EX-99.25	EX-99.25 NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on May 16, 2017, pursuant to the provisions of Rule 12d2-2 (a).
May 4, 2017	EX-99.1	2,224,199 Shares of our Common Stock Issuable upon the Exercise of one Special Warrant EX-99.1 2 bioa-ex99115.htm EX-99.1 No securities regulatory authority has expressed an opinion about any information contained herein and it is an offence to claim otherwise. This prospectus constitutes a public offering of these securities only in those jurisdictions where they may be lawfully offered for sale and only by persons permitted to sell these securities in those jurisdictions. The secu
May 4, 2017	8-K	Financial Statements and Exhibits, Other Events 8-K 1 bioa-8k20170427.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2017 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporatio
May 4, 2017	EX-99.2	BioAmber Announces Listing of Shares on Toronto Stock Exchange and Automatic Exercise of Special Warrant BioAmber Announces Listing of Shares on Toronto Stock Exchange and Automatic Exercise of Special Warrant Montreal, Canada, May 1, 2017.
April 10, 2017	EX-1	JOINT FILING AGREEMENT Joint Filing Agreement EXHIBIT 1 JOINT FILING AGREEMENT Waddell & Reed Financial, Inc.
April 10, 2017	EX-2	EXHIBIT 2 Identification and Classification of the Subsidiary Which Acquired the Security EXHIBIT 2 Waddell & Reed Investment Management Company - Tax ID No. 48-1106973 Investment Advisor registered under Section 203 of the Investment Advisors Act of 1940 Ivy Investment Management Company - Tax ID No. 03-0481447 Investment Advisor registered under Section 203 of the Investment Advisors Act of 1940
April 10, 2017	SC 13G/A	BIOA / BioAmber Inc. / WADDELL & REED FINANCIAL INC - BIOAMBER INC. Passive Investment BioAmber Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No. 5* BioAmber Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09072Q106 (CUSIP Number) March 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
April 10, 2017	EX-3	POWER OF ATTORNEY Power of Attorney EXHIBIT 3 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, THAT: The undersigned, Waddell & Reed Financial, Inc.
March 31, 2017	DEFA14A	BioAmber BIOA-DEFA14A-2017 bioa-defa14a20170331.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by
March 31, 2017	DEF 14A	BioAmber BIOA-DEF14A-2017 bioa-def14a20170511.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by R
March 31, 2017	EX-10.1	Mutual Separation Agreement by and between the Company and Mario Saucier, dated as of March 31, 2017 bioa-ex1016.htm mutual Separation Agreement THIS AGREEMENT made as of the 31st day of March, 2017, is entered into between: MR. MARIO SAUCIER, residing and domiciled at 670, des Vikings, Boucherville, Qu?bec, J4B 7S4 (hereinafter referred to as ?Mr. Saucier?) and BIOAMBER CANADA INC., a corporation duly incorporated under the Canada Business Corporations Act, having its corporate office located at
March 31, 2017	8-K	BioAmber 8-KCFO (Current Report/Significant Event) bioa-8k20170328.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2017 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Commis
March 31, 2017	EX-99.1	BioAmber Announces CFO Transition EX-99.1 3 bioa-ex9917.htm EX-99.1 BioAmber Announces CFO Transition Montreal, Canada, March 31, 2017. BioAmber Inc. (NYSE : BIOA) announced today that the Company has entered into a mutual separation agreement with Mario Saucier, in connection with his departure from his role of Chief Financial Officer effective March 28, 2017. BioAmber intends to initiate a search for a replacement CFO and until
March 16, 2017	10-K	BioAmber 10-K (Annual Report) bioa-10k20161231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001
March 16, 2017	EX-99.1	BioAmber Announces Year End Operational and Financial Results for 2016 bioa-ex9916.htm BioAmber Announces Year End Operational and Financial Results for 2016 Montreal, Canada, March 16, 2017. BioAmber Inc. (NYSE: BIOA), a leader in renewable materials, today announced operational and financial results for the three months and year ended December 31, 2016. Operational Highlights ? 2016 sales of bio-succinic acid were $8.3 million, an increase of 281% over the previous
March 16, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition bioa-8k20161231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 16, 2017 BIOAMBER INC. (Exact name of registrant as specified in its charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (C
March 16, 2017	EX-10.65	[*] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHA EX-10.65 2 bioa-ex1065516.htm EX-10.65 [*] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED NON-ASSERTION AGREEMENT This Agreement made and entered into this 21st day of Decem
February 21, 2017	8-K	BioAmber 8-K (Current Report/Significant Event) bioa-8k20170221.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2017 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Co
February 21, 2017	EX-99.1	BioAmber CEO steps down, current COO Fabrice Orecchioni named President bioa-ex9916.htm Exhibit 99.1 BioAmber CEO steps down, current COO Fabrice Orecchioni named President Montreal, February 20, 2017. BioAmber Inc. (NYSE:BIOA) announced today that Jean-Francois Huc has resigned as President and CEO and Fabrice Orecchioni, the company?s COO, has been named President, effective immediately. In his role as COO over the past four years, Fabrice has overseen the construct
February 21, 2017	EX-10.1	Mutual Separation and Consulting Agreement between the Company and Jean-Francois Huc, dated as of February 17, 2017 bioa-ex1017.htm Execution Copy Exhibit 10.1 mutual Separation and Consulting Agreement THIS AGREEMENT made as of the 17th day of February, 2017, is entered into between: MR. JEAN-FRAN?OIS HUC, residing and domiciled at 1000 Moncrieff Road, Mount Royal, Province of Quebec, H3R 3A4 (hereinafter referred to as ?Mr. Huc?) and BIOAMBER CANADA INC., a corporation duly incorporated under the Canada Busin
February 21, 2017	SC 13D/A	BIOA / BioAmber Inc. / SOFINNOVA CAPITAL VI FCPR - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
February 14, 2017	SC 13G/A	BIOA / BioAmber Inc. / WADDELL & REED FINANCIAL INC - BIOAMBER INC. Passive Investment BioAmber Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No. 4* BioAmber Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09072Q106 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th
February 14, 2017	EX-3	POWER OF ATTORNEY Power of Attorney EXHIBIT 3 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, THAT: The undersigned, Waddell & Reed Financial, Inc.
February 14, 2017	EX-1	JOINT FILING AGREEMENT Joint Filing Agreement EXHIBIT 1 JOINT FILING AGREEMENT Waddell & Reed Financial, Inc.
February 14, 2017	EX-2	EXHIBIT 2 Identification and Classification of the Subsidiary Which Acquired the Security EXHIBIT 2 Waddell & Reed Investment Management Company - Tax ID No. 48-1106973 Investment Advisor registered under Section 203 of the Investment Advisors Act of 1940 Ivy Investment Management Company - Tax ID No. 03-0481447 Investment Advisor registered under Section 203 of the Investment Advisors Act of 1940
February 13, 2017	SC 13D/A	BIOA / BioAmber Inc. / MITSUI & CO LTD - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-102) INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* BIOAMBER INC. (Name of Issuer) COMMON STOCK, $0.01 PAR VALUE PER SHARE (Title of Class of Securities) 09072Q 106 (CUSIP Number) Yoichiro Miwa Mitsui
January 30, 2017	8-K	Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2017 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Commission File Number)
January 27, 2017	EX-1.1	Underwriting Agreement EX-1.1 2 bioa-ex116.htm EX-1.1 Exhibit 1.1 Underwriting Agreement January 23, 2017 Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC As the Representative of the Several underwriters, if any, signatory hereto and named in Schedule I hereto 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: BioAmber Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and co
January 27, 2017	EX-99.1	BIOAMBER INC. INCREASES PREVIOUSLY ANNOUNCED PUBLIC OFFERING TO US$17.5 MILLION bioa-ex9918.htm Exhibit 99.1 BIOAMBER INC. INCREASES PREVIOUSLY ANNOUNCED PUBLIC OFFERING TO US$17.5 MILLION Montreal, Canada, January 24, 2017. BioAmber Inc. (NYSE: BIOA) announced that, due to strong demand, the underwriters have agreed to increase the size of the offering by 75% and purchase 3,684,212 shares of common stock of the Company, together with warrants to purchase 1,842,106 shares of
January 27, 2017	8-K	BioAmber 8-K CMPO (Current Report/Significant Event) bioa-8k20170123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2017 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Com
January 27, 2017	EX-4.1	Form of Warrant to Purchase Common Stock of BioAmber Inc. bioa-ex417.htm Exhibit 4.1 COMMON STOCK PURCHASE WARRANT bioamber inc. Warrant Shares: Initial Exercise Date: January , 2017 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after January, 2017 (the ?I
January 24, 2017	424B5	BioAmber Inc. 3,684,212 shares of common stock Warrants to purchase 1,842,106 shares of common stock 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-215408 Prospectus Supplement to Prospectus dated January 12, 2017 BioAmber Inc. 3,684,212 shares of common stock Warrants to purchase 1,842,106 shares of common stock We are offering 3,684,212 shares of our common stock, par value $0.01 per share, and common stock purchase warrants, or warrants, to purchase up to 1,842,1
January 24, 2017	FWP	UPSIZED TERM SHEET (Amended and Restated) BioAmber Inc. Public Offering of Common Stock and Warrants FWP Filed pursuant to Rule 433 Registration Statement No.: 333-215408 Issuer Free Writing Prospectus dated January 23, 2017 Relating to Preliminary Prospectus Supplement dated January 23, 2017 UPSIZED TERM SHEET (Amended and Restated) BioAmber Inc. Public Offering of Common Stock and Warrants This document does not provide full disclosure of all material facts relating to the securities offered. I
January 23, 2017	FWP	TERM SHEET BioAmber Inc. Public Offering of Common Stock and Warrants FWP Filed pursuant to Rule 433 Registration Statement No.: 333-215408 Issuer Free Writing Prospectus dated January 23, 2017 Relating to Preliminary Prospectus Supplement dated January 23, 2017 TERM SHEET BioAmber Inc. Public Offering of Common Stock and Warrants This document does not provide full disclosure of all material facts relating to the securities offered. Investors should read the final
January 23, 2017	424B5	SUBJECT TO COMPLETION, DATED JANUARY 23, 2017 424B5 1 d333680d424b5.htm 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-215408 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction whe
January 23, 2017	8-K	BioAmber 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2017 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Commission File Num
January 23, 2017	EX-99.1	BIOAMBER INC. ANNOUNCES US$10 MILLION UNDERWRITTEN PUBLIC OFFERING EX-99.1 Exhibit 99.1 BIOAMBER INC. ANNOUNCES US$10 MILLION UNDERWRITTEN PUBLIC OFFERING Montreal, Canada, January 23, 2017. BioAmber Inc. (NYSE: BIOA) today announced that it has entered into an underwriting agreement with Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC, as sole book running manager and representative of several underwriters, under which the underwriters have agreed to purc
January 3, 2017	EX-4.5	SENIOR INDENTURE BIOAMBER INC. COMPUTERSHARE TRUST COMPANY, N.A. Dated as of TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 4 Section 1.03 Incorporation by Refer EX-4.5 Exhibit 4.5 SENIOR INDENTURE BIOAMBER INC. ISSUER and COMPUTERSHARE TRUST COMPANY, N.A. TRUSTEE Dated as of TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 4 Section 1.03 Incorporation by Reference of Trust Indenture Act 4 Section 1.04 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.01 Issu
January 3, 2017	EX-4.6	SUBORDINATED INDENTURE BIOAMBER INC. COMPUTERSHARE TRUST COMPANY, N.A. Dated as of TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 4 Section 1.03 Incorporation by EX-4.6 3 d298782dex46.htm EX-4.6 Exhibit 4.6 SUBORDINATED INDENTURE BIOAMBER INC. ISSUER and COMPUTERSHARE TRUST COMPANY, N.A. TRUSTEE Dated as of TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 4 Section 1.03 Incorporation by Reference of Trust Indenture Act 5 Section 1.04 Rules of Construction 5 ARTICLE II TH
January 3, 2017	S-3	BioAmber S-3 S-3 1 d298782ds3.htm S-3 Table of Contents As filed with the Securities and Exchange Commission on January 3, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOAMBER INC. (Exact name of Registrant as specified in its charter) Delaware 98-0601045 (State or other jurisdiction of incor
December 29, 2016	EX-4.2	Warrant Agency Agreement dated as of December 29, 2016 by and between BioAmber Inc. and Computershare Inc. EX-4.2 Exhibit 4.2 BIOAMBER INC. WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT (this ?Warrant Agreement?) made as of December 29, 2016 (the ?Issuance Date?), among BioAmber Inc., a Delaware corporation (?Company?), and Computershare Inc., a Delaware corporation (?Computershare?), and its wholly-owned subsidiary, Computershare Trust Company, N.A., a federally chartered trust company (together w
December 29, 2016	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2016 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Commission File Nu
December 29, 2016	EX-1.2	CANADIAN SECURITIES PURCHASE AGREEMENT EX-1.2 Exhibit 1.2 CANADIAN SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of December 22, 2016, between BioAmber Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and c
December 29, 2016	EX-1.1	Underwriting Agreement EX-1.1 2 d274028dex11.htm EX-1.1 Exhibit 1.1 Underwriting Agreement December 22, 2016 H.C. Wainwright & Co., LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: BioAmber Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to t
December 29, 2016	EX-4.1	Form of Warrant to Purchase Common Stock of BioAmber Inc. EX-4.1 Exhibit 4.1 Warrant No. December , 2016 UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE THE DATE THAT IS 4 MONTHS AND A DAY AFTER THE LATER OF (I) [insert date of issuance of Warrant] AND (II) THE DATE THAT THE ISSUER BECAME A REPORTING ISSUER IN ANY PROVINCE OR TERRITORY WARRANT TO PURCHASE COMMON STOCK OF BIOAMBER INC. BioAmber
December 29, 2016	EX-99.1	BIOAMBER INC. ANNOUNCES $7 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK AND CONCURRENT $8.9 MILLION REGISTERED DIRECT OFFERING OF WARRANTS EX-99.1 Exhibit 99.1 BIOAMBER INC. ANNOUNCES $7 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK AND CONCURRENT $8.9 MILLION REGISTERED DIRECT OFFERING OF WARRANTS Montreal, Canada, December 23, 2016. BioAmber Inc. (NYSE: BIOA), a leader in renewable materials, today announced that it has priced an underwritten offering of 1,748,750 shares of its common stock at a price of $4.00 per share. The gross
December 23, 2016	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2016 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Commission File Number
December 23, 2016	424B5	BioAmber Inc. Warrants to purchase up to 2,224,199 shares of common stock 424B5 1 d282336d424b5.htm 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-196470 Prospectus Supplement to Prospectus, dated July 9, 2014 BioAmber Inc. Warrants to purchase up to 2,224,199 shares of common stock We are offering warrants to purchase up to 2,224,199 shares of our common stock in this offering (and the shares of common stock issuable from time to time upo
December 23, 2016	424B5	BioAmber Inc. 1,748,750 shares of common stock 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-196470 Prospectus Supplement to Prospectus, dated July 9, 2014 BioAmber Inc. 1,748,750 shares of common stock We are offering 1,748,750 shares of our common stock in this offering. Our common stock is traded on the New York Stock Exchange under the symbol BIOA. The last reported sale price of our common stock on the Ne
December 23, 2016	S-3MEF	BioAmber S-3MEF S-3MEF As filed with the Securities and Exchange Commission on December 22, 2016 Registration No.
November 7, 2016	10-Q	BioAmber FORM 10-Q (Quarterly Report) 10-Q 1 bioa-10q20160930.htm FORM 10-Q è UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission
November 7, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 3, 2016 BIOAMBER INC. (Exact name of registrant as specified in its charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Commission File Num
November 7, 2016	EX-99.2	FINAL TRANSCRIPT BioAmber Inc. Third Quarter 2016 Results Conference Call Event Date/Time: November 3, 2016 — 4:30 p.m. E.T. Length: 24 minutes EX-99.2 3 bioa-ex99219.htm EX-99.2 Exhibit 99.2 FINAL TRANSCRIPT BioAmber Inc. Third Quarter 2016 Results Conference Call Event Date/Time: November 3, 2016 — 4:30 p.m. E.T. Length: 24 minutes 1 FINAL TRANSCRIPT November 3, 2016 — 4:30 p.m. E.T. BioAmber Inc. Third Quarter 2016 Results Conference Call Corporate participants Roy McDowall BioAmber Inc. — Senior Vice President, Communication & Strateg
November 7, 2016	EX-99.1	BioAmber Reports Third Quarter 2016 Financial and Operational Results bioa-ex9916.htm Exhibit 99.1 BioAmber Reports Third Quarter 2016 Financial and Operational Results Montreal, Canada, November 3, 2016. BioAmber Inc. (NYSE: BIOA), a leader in renewable materials, today announced financial and operational results for the three months ending September 30, 2016. Highlights • Q3 2016 Sales of bio-succinic acid were $3.7 million, an increase of 45% over the previous qu
November 7, 2016	EX-10.1	Letter Agreement Offer of financing with BioAmber Inc. and Bridging Finance Inc. dated as of September 9, 2016 EX-10.1 2 bioa-ex101112.htm EX-10.1 Exhibit 10.1 September 9th, 2016 BioAmber Inc. 1250 Rene-Levesque Blvd. West, Suite 4310 Montreal, Quebec, Canada H3B 4W8 Attention: President & CEO Dear Mr. Jean-François Huc: Re: Bridging Finance Inc. (in its capacity as lender, the “Lender”), demand non-revolving credit facility in favour of the Borrower (as defined below) The Lender is pleased to offer the c
September 14, 2016	8-K	BioAmber 8-K (Current Report/Significant Event) bioa-8k20160909.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 9, 2016 BIOAMBER INC. (Exact name of registrant as specified in its charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation)
August 9, 2016	8-K/A	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant bioa-8ka20160420.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 20, 2016 BIOAMBER INC. (Exact name of registrant as specified in its charter) Delaware 001-35905 98-0601045 (State or other jurisdiction
August 9, 2016	8-K/A	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant bioa-8ka20160420.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 20, 2016 BIOAMBER INC. (Exact name of registrant as specified in its charter) Delaware 001-35905 98-0601045 (State or other jurisdiction
August 9, 2016	10-Q	BioAmber FORM 10-Q (Quarterly Report) 10-Q 1 bioa-10q20160630.htm FORM 10-Q è UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file
August 9, 2016	10-Q	BioAmber FORM 10-Q (Quarterly Report) 10-Q 1 bioa-10q20160630.htm FORM 10-Q è UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file
August 9, 2016	EX-99.1	BioAmber Reports Second Quarter 2016 Financial Results EX-99.1 2 bioa-ex9917.htm EX-99.1 BioAmber Reports Second Quarter 2016 Financial Results Montreal, Canada, August 9, 2016. BioAmber Inc. (NYSE: BIOA), a leader in renewable materials, today announced operational and financial results for the three months ending June 30, 2016. “BioAmber continues to meet ramp-up expectations at its Sarnia plant. We have made excellent progress in the plant’s reliab
August 9, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 9, 2016 BIOAMBER INC. (Exact name of registrant as specified in its charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Commission File Numbe
August 9, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 9, 2016 BIOAMBER INC. (Exact name of registrant as specified in its charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Commission File Numbe
August 9, 2016	EX-10.1	Letter of Offer of financing with BioAmber Sarnia Inc. and BDC Capital Inc. dated as of April 19, 2016 Exhibit 10.1 April 19, 2016 BioAmber Sarnia Inc. 1201 Vidal Street South Sarnia, Ontario N7T 7M2 Attention of:Mario Saucier, Chief Financial Officer Re:Letter of Offer of financing no. 101222-01 granted to BioAmber Sarnia Inc. Sir, On the basis of the preliminary information obtained from the Borrower and subject to the acceptance of the present letter of offer of financing, as amended from time t
May 20, 2016	8-K	Submission of Matters to a Vote of Security Holders bioa-8k20160519.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 19, 2016 BIOAMBER INC. (Exact name of registrant as specified in its charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Com
May 9, 2016	EX-10.1	Second Amended and Restated Joint Venture Agreement dated as of February 15, 2016 among the Registrant, Mitsui & Co., Ltd. and the other parties thereto CONFIDENTIAL Execution Version SECOND AMENDED AND RESTATED JOINT VENTURE AGREEMENT by and among BIOAMBER INC.
May 6, 2016	10-Q	BioAmber 10-Q (Quarterly Report) bioa-10q20160331.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35905
May 3, 2016	EX-99.1	BioAmber Reports First Quarter 2016 Financial Results bioa-ex9917.htm BioAmber Reports First Quarter 2016 Financial Results Montreal, Canada, May 3, 2016. BioAmber Inc. (NYSE: BIOA), a leader in renewable materials, today announced operational and financial results for the three months ended March 31, 2016. Highlights included: ? Production in the first quarter continued to ramp up, with plant up-time averaging 70% in the last three weeks of the quar
May 3, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition bioa-8k20160503.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 3, 2016 BIOAMBER INC. (Exact name of registrant as specified in its charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Comm
April 26, 2016	8-K	BioAmber 8-K (Current Report/Significant Event) bioa-8k20160420.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 20, 2016 BIOAMBER INC. (Exact name of registrant as specified in its charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (C
April 6, 2016	DEFA14A	BioAmber DEFA14A bioa-defa14a_20160430.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by
April 6, 2016	DEF 14A	BioAmber DEF 14A bioa-def14a20160519.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by R
March 15, 2016	10-K	BioAmber 10-K (Annual Report) 10-K 1 bioa-10k20151231.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file
March 15, 2016	EX-10.61	Settlement & Technology Access Agreement between BioAmber Inc. and Reverdia V.O.F., dated December 15, 2015 CONFIDENTIAL Privileged SETTLEMENT & TECHNOLOGY ACCESS AGREEMENT relating to Biosuccinium™ Technology between Reverdia V.
March 14, 2016	EX-99.1	BioAmber Announces Year End Operational and Financial Results for 2015 bioa-ex99122.htm Appendix 99.1 BioAmber Announces Year End Operational and Financial Results for 2015 Montreal, Canada, March 14, 2016. BioAmber Inc. (NYSE: BIOA), a leader in renewable materials announced operational and financial results for the three months and year ended December 31, 2015. The highlights included: ? Sales of bio-succinic acid in the fourth quarter were $1.1 million, including
March 14, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 14, 2016 BIOAMBER INC. (Exact name of registrant as specified in its charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Commission File Numbe
February 26, 2016	EX-99.1	BioAmber Announces Changes to its Board of Directors bioa-ex991_43.htm BioAmber Announces Changes to its Board of Directors Feb 22, 2016 MONTREAL, Feb. 22, 2016 - BioAmber Inc. (NYSE: BIOA), a leader in renewable materials, today announced that George F.J. Gosbee is joining its board of directors, effective today. Mr. Gosbee will replace Henry "Pete" Linsert, Jr. who resigned his board seat for personal reasons, effective today. George Gosbee brings
February 26, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits bioa-8k20160222.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2016 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Co
February 16, 2016	SC 13G/A	BIOA / BioAmber Inc. / ARROWGRASS CAPITAL PARTNERS (US) LP - ARROWGRASS CAPITAL PARTNERS (US) LP Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2) BioAmber Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 09072Q106 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
February 12, 2016	EX-3	POWER OF ATTORNEY Power of Attorney EXHIBIT 3 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, THAT: The undersigned, Waddell & Reed Financial, Inc.
February 12, 2016	EX-2	EXHIBIT 2 Identification and Classification of the Subsidiary Which Acquired the Security EXHIBIT 2 Waddell & Reed Investment Management Company - Tax ID No. 48-1106973 Investment Advisor registered under Section 203 of the Investment Advisors Act of 1940 Ivy Investment Management Company - Tax ID No. 03-0481447 Investment Advisor registered under Section 203 of the Investment Advisors Act of 1940
February 12, 2016	EX-1	JOINT FILING AGREEMENT Joint Filing Agreement EXHIBIT 1 JOINT FILING AGREEMENT Waddell & Reed Financial, Inc.
February 12, 2016	SC 13G/A	BIOA / BioAmber Inc. / WADDELL & REED FINANCIAL INC - BIOAMBER INC. Passive Investment SC 13G/A 1 d120476dsc13ga.htm BIOAMBER INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No. 3* BioAmber Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09072Q106 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
February 12, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement bioa-8k20160208.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8?K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2016 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Com
January 19, 2016	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 d123143d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2016 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or Other Jurisdiction of Incorporation)
January 19, 2016	EX-99.1	BIOAMBER INC. ANNOUNCES PUBLIC OFFERING OF COMMON STOCK EX-99.1 4 d123143dex991.htm EX-99.1 Exhibit 99.1 BIOAMBER INC. ANNOUNCES PUBLIC OFFERING OF COMMON STOCK Montreal, Canada, January 14, 2016. BioAmber Inc. (NYSE: BIOA), a leader in renewable materials, today announced that it has commenced an underwritten public offering of its common stock. In addition, BioAmber expects to grant the underwriters a 30-day option to purchase up to an additional 15
January 19, 2016	EX-1.1	Underwriting Agreement EX-1.1 2 d123143dex11.htm EX-1.1 Exhibit 1.1 Underwriting Agreement January 15, 2016 H.C. Wainwright & Co., LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: BioAmber Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to th
January 19, 2016	424B5	BioAmber Inc. 2,600,000 shares of common stock 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-196470 Prospectus Supplement to Prospectus dated July 9, 2014 BioAmber Inc. 2,600,000 shares of common stock We are offering 2,600,000 shares of our common stock in this offering. Our common stock is traded on the New York Stock Exchange under the symbol ?BIOA.? The last reported sale price of our common stock on the New
January 19, 2016	EX-99.2	BIOAMBER INC. ANNOUNCES PRICING OF $13.0 MILLION PUBLIC OFFERING EX-99.2 Exhibit 99.2 BIOAMBER INC. ANNOUNCES PRICING OF $13.0 MILLION PUBLIC OFFERING Montreal, Canada, January 15, 2016. BioAmber Inc. (NYSE: BIOA), a leader in renewable materials, today announced that it has priced an underwritten public offering of 2,600,000 shares of its common stock at a price of $5.00 per share. The gross proceeds to the Company will be $13.0 million. The offering is expect
January 14, 2016	424B5	Subject To Completion, Dated January 14, 2016 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-196470 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is no
December 28, 2015	8-K	Current Report 8-K 1 bioa-8k20151228.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2015 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorpor
December 18, 2015	8-K	Entry into a Material Definitive Agreement 8-K 1 bioa-8k20151214.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2015 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorpor
December 17, 2015	EX-10.1	Third Amendment to Loan and Security Agreement, dated as of December 16, 2015, between the Company, Special Value Continuation Partners, LP and Obsidian Agency Services, Inc. EX-10.1 2 bioa-ex1016.htm EX-10.1 Exhibit 10.1 THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT LOAN AND SECURITY AGREEMENT (this “Amendment”) dated as of December 16, 2015, between BioAmber Inc., a Delaware corporation (“Borrower”), each Lender and Obsidian Agency Services, Inc., a California corporation, in its capacity as administrative and collateral Agent (the “Agent”) for
December 17, 2015	8-K	BioAmber 8-K (Current Report/Significant Event) bioa-8k20151216.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8?K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2015 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Co
November 17, 2015	EX-10.2	Consulting Agreement, dated September 28, 2015, between the Company and Mario Saucier. bioa-ex1027.htm Exhibit 10.2 CONSULTING AGREEMENT This Consulting Agreement (this ?Agreement?), effective as of September 28, 2015 (the ?Effective Date?), is made by and between BioAmber Inc., having a corporate office located at 1250 Rene-Levesque Blvd West, Suite 4310, Montreal, Quebec, Canada H3B 4W8 (the ?Corporation?) and Mr. Mario Saucier, residing and domiciled at 670, des Vikings, Boucherv
November 17, 2015	EX-99.1	BioAmber Announces Hiring of Chief Financial Officer bioa-ex991_9.htm Exhibit 99.1 BioAmber Announces Hiring of Chief Financial Officer Montreal, Canada, November 16, 2015. BioAmber Inc. (NYSE: BIOA), a leader in renewable materials, has recruited Mario Saucier to serve as its Chief Financial Officer, effective January 4, 2016. Andrew Ashworth, who came out of retirement in July 2015 to act as Chief Financial Officer on an interim basis, will leave
November 17, 2015	EX-10.3	EMPLOYMENT AGREEMENT bioa-ex103_8.htm Exhibit 10.3 EMPLOYMENT AGREEMENT ENTERED INTO as of July 28th, 2015 (the “Effective Date”). BETWEEN: BIOAMBER INC., a corporation duly incorporated in Delaware, having a corporate office located at 1250 Rene-Levesque West, Suite 4310, Montreal, Quebec, Canada H3B 4W8, represented for the purposes hereof by Jean-Francois Huc, its Chief Executive Officer, duly authorized as he so d
November 17, 2015	EX-10.1	Employment Agreement, dated September 28, 2015, between the Company and Mario Saucier bioa-ex101_6.htm Exhibit 10.1 EMPLOYMENT AGREEMENT ENTERED INTO as of September 28th, 2015. BETWEEN: BIOAMBER CANADA INC., a corporation duly incorporated in Canada, having a business place located at 1250 Rene-Levesque West, Suite 4310, Montreal, Quebec, H3B 4W8, represented for the purposes hereof by Mr. Jean-Francois Huc, its President, duly authorized as he so declares; (hereinafter referred t
November 17, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits bioa-8k20151116.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 16, 2015 BIOAMBER INC. (Exact name of registrant as specified in its charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation)
November 9, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35905 BIOAMBER INC. (E
November 4, 2015	EX-99.1	BioAmber Announces Operational and Financial Results for Q3 2015 bioa-ex991_77.htm BioAmber Announces Operational and Financial Results for Q3 2015 Montreal, Canada, November 4, 2015. BioAmber Inc. (NYSE: BIOA), a leader in renewable materials announced operational and financial results for the quarter ending September 30, 2015. The key operational highlights include: · Sarnia is producing high quality succinic acid that has been qualified by a number of custom
November 4, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 bioa-8k20151104.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 4, 2015 BIOAMBER INC. (Exact name of registrant as specified in its charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incor
August 5, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35905 BIOAMBER INC. (Exact
August 4, 2015	EX-10.1	Second Amendment to Loan and Security Agreement, dated as of July 29, 2015, between the Company, Special Value Continuation Partners, LP and Obsidian Agency Services, Inc. bioa-ex1016.htm Exihibit 10.1 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT LOAN AND SECURITY AGREEMENT (this ?Amendment?) dated as of July 29th, 2015, (the ?Effective Date?) between BioAmber Inc., a Delaware corporation (?Borrower?), each Lender and Obsidian Agency Services, Inc., a California corporation, in its capacity as administrative and collateral Agent (the ?Agent?
August 4, 2015	8-K	BioAmber 8-K (Current Report/Significant Event) bioa-8k20150804.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 4, 2015 BIOAMBER INC. (Exact name of registrant as specified in its charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (C
August 4, 2015	8-K	BioAmber 8-K (Current Report/Significant Event) bioa-8k20140729.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 29, 2015 BIOAMBER INC. (Exact name of registrant as specified in its charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Co
August 4, 2015	EX-99.1	BioAmber Reports Second Quarter 2015 Financial Results EX-99.1 2 bioa-ex99119.htm EX-99.1 - PRESS RELEASE Exhibit 99.1 BioAmber Reports Second Quarter 2015 Financial Results Montreal, Canada, August 4, 2015. BioAmber Inc. (NYSE: BIOA), a leader in renewable materials today announced its financial results for the quarter ending June 30, 2015. Highlights included: · The Sarnia plant achieved mechanical completion in June 2015 · The final cost of the Sar
July 29, 2015	8-K	BioAmber 8-K (Current Report/Significant Event) bioa-8k20150729.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 29, 2015 BIOAMBER INC. (Exact name of registrant as specified in its charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Co
July 29, 2015	EX-99.1	BioAmber Announces Change in Chief Financial Officer bioa-ex9916.htm Exhibit 99.1 BioAmber Announces Change in Chief Financial Officer Montreal, Canada, July 29, 2015. BioAmber Inc. (NYSE: BIOA) today announced that Francois Laurin, the Company?s Chief Financial Officer has resigned. The Company has hired Andrew Ashworth, its former Chief Financial Officer who retired in December 2014, as full time interim CFO and has launched a search for a permane
May 19, 2015	8-K	BioAmber 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 15, 2015 BIOAMBER INC. (Exact name of registrant as specified in its charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Commission File Number)
May 19, 2015	8-K	BioAmber 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2015 BIOAMBER INC. (Exact name of registrant as specified in its charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Commission File Number)
May 19, 2015	EX-10.1	Amended and Restated 2013 Stock Option and Incentive Plan of the Registrant and Forms of Award Agreements thereunder Exhibit 10.1 BIOAMBER INC. AMENDED AND RESTATED 2013 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the BioAmber Inc. Amended and Restated 2013 Stock Option and Incentive Plan (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and other key persons (including Consultants and p
May 11, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 bioa-10q20150331.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe
May 7, 2015	8-K	BioAmber 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 7, 2015 BIOAMBER INC. (Exact name of registrant as specified in its charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Commission File Number)
May 7, 2015	EX-99.1	BioAmber Reports First Quarter 2015 Financial Results Exhibit 99.1 BioAmber Reports First Quarter 2015 Financial Results Minneapolis, MN, May 7, 2015. BioAmber Inc. (NYSE: BIOA), an industrial biotechnology company producing sustainable chemicals, today announced its financial results for the quarter ending March 31, 2015. Highlights included: The Sarnia plant remains on track to begin commercial operations in Q3 2015, with project costs that continu
May 4, 2015	EX-1.1	Underwriting Agreement EX-1.1 2 d918073dex11.htm EX-1.1 Exhibit 1.1 Underwriting Agreement May 1, 2015 Canaccord Genuity Inc. As representative of the several Underwriters named in Schedule I hereto c/o Canaccord Genuity Inc. 99 High Street, Suite 1200 Boston, Massachusetts 02110 Ladies and Gentlemen: BioAmber Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to i
May 4, 2015	EX-99.2	BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering EX-99.2 5 d918073dex992.htm EX-99.2 Exhibit 99.2 BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering Minneapolis, MN, May 1, 2015. BioAmber Inc. (NYSE: BIOA), an industrial biotechnology company producing sustainable chemicals, today announced that it has priced an underwritten registered offering of 3,900,000 shares of its common stock at a price of $9.00 per share, and granted t
May 4, 2015	424B5	BioAmber Inc. 3,900,000 Shares of Common Stock 424B5 1 d917394d424b5.htm 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-196470 Prospectus Supplement to Prospectus dated July 9, 2014 BioAmber Inc. 3,900,000 Shares of Common Stock We are offering 3,900,000 shares of our common stock in this offering. Our common stock is traded on the New York Stock Exchange under the symbol “BIOA.” The last reported sale price of o
May 4, 2015	8-K	BioAmber FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2015 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or Other Jurisdiction of Incorporation) (Commission File Num
May 4, 2015	EX-99.1	BioAmber Inc. Announces Public Offering Of Common Stock EX-99.1 Exhibit 99.1 BioAmber Inc. Announces Public Offering Of Common Stock Minneapolis, MN, April 30, 2015. BioAmber Inc. (NYSE: BIOA), an industrial biotechnology company producing sustainable chemicals, today announced that it has commenced an underwritten public offering of its common stock. In addition, BioAmber expects to grant the underwriters a 30-day option to purchase up to an additiona
May 4, 2015	EX-99.3	Information Relating to Item 14 – Other Expenses of Issuance and Distribution EX-99.3 Exhibit 99.3 Information Relating to Item 14 ? Other Expenses of Issuance and Distribution The expenses to be paid by BioAmber Inc. (the ?Company?) in connection with the offering and sale of the Company?s common stock pursuant to the Company?s registration statement, File No. 333-196470 (the ?Registration Statement?), other than underwriting discounts and commission, are set forth in the
April 30, 2015	424B5	Subject To Completion, Dated April 30, 2015 424b5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-196470 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is no
April 30, 2015	10-K/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 Commission File Number 001-35905 BI 10-K/A 1 d919860d10ka.htm 10-K/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 Commission File Number 001-35905 BIOAMBER INC. (Exact name of registrant as specified in its charter) Delaware 20-1579162 (State or other jurisdiction o
April 2, 2015	DEF 14A	BioAmber DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin
April 2, 2015	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin
March 16, 2015	EX-10.67	Loan and Security Agreement, dated as of December 17, 2014, among Tennenbaum Capital Partners, Sinoven Biopolymers Inc., BioAmber Canada Inc. and BioAmber International S.a.r.l. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this ?Agreement?) dated as of December 17, 2014, (the ?Effective Date?) between BioAmber Inc.
March 16, 2015	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35905 BioAmber Inc.
March 16, 2015	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Name Jurisdiction of Organization AmberWorks LLC Delaware BioAmber Sarnia Inc. Canada Omitted from the table are those subsidiaries which are not significant subsidiaries (as defined in rule 1-02(w) of Regulation S-X of the Securities Exchange Act of 1934, as amended) and in the aggregate would not constitute a significant subsidiary.
March 12, 2015	8-K	BioAmber 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 12, 2015 BIOAMBER INC. (Exact name of registrant as specified in its charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Commission File Numbe
March 12, 2015	EX-99.1	BioAmber Reports Fourth Quarter and Full Year 2014 Financial Results Exhibit 99.1 BioAmber Reports Fourth Quarter and Full Year 2014 Financial Results Minneapolis, MN, March 12, 2015. BioAmber Inc. (NYSE: BIOA), an industrial biotechnology company producing sustainable chemicals including bio-based succinic acid, today announced its financial results for the fourth quarter and year ended December 31, 2014. Highlights included: ? Substantial progress was made on con
February 13, 2015	EX-2	EXHIBIT 2 Identification and Classification of the Subsidiary Which Acquired the Security EXHIBIT 2 Waddell & Reed Investment Management Company - Tax ID No. 48-1106973 Investment Advisor registered under Section 203 of the Investment Advisors Act of 1940 Ivy Investment Management Company - Tax ID No. 03-0481447 Investment Advisor registered under Section 203 of the Investment Advisors Act of 1940
February 13, 2015	EX-3	POWER OF ATTORNEY Power of Attorney EXHIBIT 3 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, THAT: The undersigned, Waddell & Reed Financial, Inc.
February 13, 2015	SC 13G/A	BIOA / BioAmber Inc. / WADDELL & REED FINANCIAL INC - BIOAMBER INC. Passive Investment BioAmber Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No. 2* BioAmber Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09072Q106 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th
February 13, 2015	EX-1	JOINT FILING AGREEMENT Joint Filing Agreement EXHIBIT 1 JOINT FILING AGREEMENT Waddell & Reed Financial, Inc.
February 4, 2015	SC 13G/A	BIOA / BioAmber Inc. / ARROWGRASS CAPITAL PARTNERS (US) LP - ARROWGRASS CAPITAL PARTNERS (US) LP Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) BioAmber Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 09072Q106 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
January 6, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K 1 bioa-8k20150501.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 6, 2015 BIOAMBER INC. (Exact name of registrant as specified in its charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorp
January 6, 2015	EX-99.1	BioAmber Announces New Chief Financial Officer and Change to the Board BioAmber Announces New Chief Financial Officer and Change to the Board Minneapolis, MN, January 6, 2015.
January 6, 2015	EX-10.1	EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT ENTERED INTO as of December 2nd, 2014. BETWEEN: BIOAMBER CANADA INC., a corporation duly incorporated in Canada, having a business place located at 1250 Rene-Levesque West, Suite 4110, Montreal, Quebec, H3B 4W8, represented for the purposes hereof by Mr. Jean-Francois Huc, its President, duly authorized as he so declares; (hereinafter referred to as the "Corporation") AND: MR.
December 19, 2014	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 19, 2014 BIOAMBER INC. (Exact name of registrant as specified in its charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Commission File Nu
November 12, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35905 BIOAMBER INC. (E
November 6, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 6, 2014 BIOAMBER INC. (Exact name of registrant as specified in its charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Commission File Num
November 6, 2014	EX-99.1	BioAmber Reports Third Quarter 2014 Financial Results Exhibit 99.1 BioAmber Reports Third Quarter 2014 Financial Results Minneapolis, MN, November 6, 2014. BioAmber Inc. (NYSE: BIOA), an industrial biotechnology company producing sustainable chemicals, today announced its financial results for the third quarter ended September 30, 2014. Highlights included: · Sarnia project continues to be on budget and scheduled for mechanical completion in early 20
August 12, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35905 BIOAMBER INC. (Exact
August 12, 2014	EX-10.1	Loan Agreement, dated as of June 30, 2014, among BioAmber Sarnia Inc., Comerica Bank and the other parties thereto. Execution Version $20,000,000 LOAN AGREEMENT BIOAMBER SARNIA INC. as Borrower THE LENDERS PARTY HERETO COMERICA BANK as Agent Dated as of June 20, 2014 Table of Contents Article 1 DEFINITIONS AND INTERPRETATION 1 1.1 Definitions 1 1.2 Extended Meanings 33 1.3 References to Agreements and Documents 36 1.4 Reference to Statutes 37 1.5 Headings and Schedules 37 1.6 Grammatical Variations 37 1.7 Accou
August 7, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 7, 2014 BIOAMBER INC. (Exact name of registrant as specified in its charter) Delaware 001-35905 98-0601045 (State or other jurisdiction of incorporation) (Commission File Numbe
August 7, 2014	EX-99.1	BioAmber Reports Second Quarter 2014 Financial Results Exhibit 99.1 BioAmber Reports Second Quarter 2014 Financial Results Minneapolis, MN, August 7, 2014. BioAmber Inc. (NYSE: BIOA), an industrial biotechnology company producing sustainable chemicals, today announced its financial results for the quarter ended June 30, 2014. Highlights for the quarter included: · Sarnia project continues to be on budget and scheduled for completion in early 2015 · An
July 21, 2014	EX-99.1	BIOAMBER INC. ANNOUNCES PUBLIC OFFERING OF COMMON STOCK Exhibit 99.1 News Release FOR IMMEDIATE RELEASE BIOAMBER INC. ANNOUNCES PUBLIC OFFERING OF COMMON STOCK MINNEAPOLIS, MN, July 15, 2014 – BioAmber Inc. (NYSE: BIOA), an industrial biotechnology company producing sustainable chemicals, today announced that it has commenced a public offering of 2,800,000 shares of its common stock. The underwriters will have a 30-day option from the date of the offer
July 21, 2014	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 d758791d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2014 BIOAMBER INC. (Exact name of registrant as specified in charter) Delaware 001-35905 98-0601045 (State or Other Jurisdiction of Incorporatio
July 21, 2014	EX-1.1	BioAmber Inc. Common Stock, par value $0.01 per Share Underwriting Agreement EX-1.1 Exhibit 1.1 EXECUTION VERSION BioAmber Inc. Common Stock, par value $0.01 per Share Underwriting Agreement July 16, 2014 Credit Suisse Securities (USA) LLC Canaccord Genuity Inc. As representatives of the several Underwriters named in Schedule I hereto c/o Credit Suisse Securities (USA) LLC 11 Madison Avenue New York, New York 10010-3629 Canaccord Genuity Inc. 99 High Street, Suite 1200 Bos

BIOA / BioAge Labs, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)

Other Listings